ID: ALA2380417

Max Phase: Preclinical

Molecular Formula: C23H21NO2

Molecular Weight: 343.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCn1cc(C(=O)c2cccc3ccccc23)c2cccc(O)c21

Standard InChI:  InChI=1S/C23H21NO2/c1-2-3-14-24-15-20(18-11-7-13-21(25)22(18)24)23(26)19-12-6-9-16-8-4-5-10-17(16)19/h4-13,15,25H,2-3,14H2,1H3

Standard InChI Key:  RERSSQCTZKUWMM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 343.43

Molecular Weight (Monoisotopic): 343.1572

AlogP: 5.53

#Rotatable Bonds: 5

Polar Surface Area: 42.23

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.03

CX Basic pKa:

CX LogP: 5.76

CX LogD: 5.75

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.48

Np Likeness Score: -0.40

References

1. Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE..  (2013)  Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.,  56  (11): [PMID:23631463] [10.1021/jm400268b]

2.  (2016)  Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases, 

Source

Source(2):

• Scientific Literature
• BindingDB Database